CRISPR: Pursuit of profit poisons collaboration

The CRISPR–Cas9 patent battle demonstrates how overzealous efforts to commercialize technology can damage science, writes Jacob S. Sherkow.

See it on Scoop.it, via Tampa Florida Public Relations